Brian Douglas, PA
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,007 of the $6,737 with a category attached, or 74.3%. 29 manufacturers reported payments, led by Medtronic at 36.2% of the total. 2025 is the largest year on record at $2,763, 3.3 times the $837 reported in 2022.
Across 195 payments — averaging $34.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Saluda Medical Americas, Inc.$673
- Tersera Therapeutics LLC$513
- AbbVie$472
- Pfizer$243
- Scilex Pharmaceuticals Inc.$221
- plus $2K from 23 others
What the payments were for
- Travel & lodging$1,38521%
- Food & beverage$5,00774%
- Education$3455%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 27 | $2,436 |
| Saluda Medical Americas, Inc. | 35 | $673 |
| Tersera Therapeutics LLC | 10 | $513 |
| AbbVie | 26 | $472 |
| Pfizer | 14 | $243 |
| Scilex Pharmaceuticals Inc. | 12 | $221 |
| Nevro Corp. | 4 | $212 |
| SPR Therapeutics, Inc | 4 | $204 |
| Averitas Pharma Inc. | 8 | $196 |
| Collegium Pharmaceutical, Inc. | 8 | $183 |
| Nalu Medical, Inc. | 2 | $161 |
| GRT US Holding, Inc. | 7 | $158 |
| Vertos Medical, Inc. | 2 | $150 |
| Relievant Medsystems, Inc. | 1 | $120 |
| Boston Scientific | 4 | $113 |
| IBSA Pharma Inc. | 4 | $93 |
| Merz Pharmaceuticals, LLC | 3 | $92 |
| Vertex | 4 | $85 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $79 |
| Sanofi-aventis U.S. LLC | 2 | $65 |
| Amgen | 3 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Bioventus LLC | 1 | $29 |
| Upsher-smith Laboratories LLC | 1 | $27 |
| Globus Medical | 1 | $26 |
| Pacira Pharmaceuticals Incorporated | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Convatec Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$1,007
- INTELLIS ADAPTIVESTIM$569
- Intracept$478
- Nalu Neurostimulation System$137
- mild Device Kit$133
- SPRINT PNS System$132
- Qutenza$123
- PRIALT$119
- Omnia$113
- INCEPTIV$110
How this compares
$6,737 in reported general payments places this provider in the 85th percentile of 250 medical providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 19 | $31,044 |
| BelbucaBuprenorphine Hcl | 21 | $20,823 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 458 | $14,268 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 618 | $14,071 |
| OxycontinOxycodone Hcl | 23 | $13,810 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 83 | $13,119 |
| Buprenorphine | 46 | $12,353 |
| LinzessLinaclotide | 23 | $12,046 |
| Xtampza ErOxycodone Myristate | 18 | $11,418 |
| Oxycodone Hcl | 543 | $10,382 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $10,300 |
| Gabapentin | 406 | $7,759 |
| Pregabalin | 235 | $6,076 |
| Lidocaine | 21 | $3,691 |
| Morphine Sulfate ErMorphine Sulfate | 116 | $2,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $183 | $32,24139 claims |
| PfizerNurtec Odt | $243 | $31,04419 claims |
| AbbVieLinzess | $472 | $12,04623 claims |
| Upsher-smith Laboratories LLCTopiramate | $27 | $37635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 medical providers in Nevada.
Other medical in Reno
- Ashley OwensReno$7K
- Christine BurnsReno$7K
- Sarah GutierrezReno$6K
- Bradley BusReno$6K
- Melissa ShelleyReno$6K
- Gretchen GoicoecheaReno$5K
- Nicholas BeaudetteReno$4K
- Shaylee NystromReno$4K
- Sheila QuinnReno$4K
- Carla ChongReno$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.